This study evaluated the suitability of the SureSeq™ Myeloid MRD Complete NGS Workflow Solution V2 for detection of low-level variants in measurable residual disease (MRD) monitoring. The results show that this NGS approach can reliably detect AML-related genetic variants for SNVs, indels and FLT3-ITDs as low as 0.05% VAF, enabling stronger characterisation of the AML status of research samples.
Read and download the Scientific posterThis study demonstrates the SureSeq™ Myeloid Fusion Complete NGS Workflow Solution V2’s 100% concordance with qPCR and FISH for detecting known chromosomal rearrangements in acute myeloid leukaemia (AML). In addition, the NGS-based approach provides a more comprehensive transcriptomic landscape of fusions in myeloid leukaemias.
Read and download the Scientific posterThis study highlights the ability of the SureSeq™ Myeloid Fusion Panel to detect multiple fusions, identify breakpoints, and capture MECOM overexpression, so your lab can achieve higher efficiency sample classification with a single assay.
Read and download the App noteFirst presented at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, this scientific poster demonstrates the capabilities of our SureSeq™ CLL + CNV V3 Panel in detecting copy number alterations and gene variants in Chronic Lymphocytic Leukaemia (CLL).
Read and download the Scientific posterPresented at the 14th Annual Meeting of the Cancer Genomics Consortium, this poster demonstrates our measurable residual disease (MRD) next generation sequencing (NGS) capabilities in acute myeloid leukaemia (AML) monitoring.
Read and download the Scientific posterThe aim of this study is to evaluate a modified version of the OGT™ Universal NGS Workflow Solution in conjunction with a custom SureSeq™ targeted panel for use with cfDNA.
Read and download the Scientific posterPresented at the AMP 2020 virtual meeting, this poster demonstrates the capability of the SureSeq™ Breast Cancer + CNV Panel in combination with Interpret software to detect germline and mosaic CNVs.
Read and download the Scientific posterThis technical note compares performance of CytoSure Constitutional NGS and a range of microarrays for 255 research samples processed in three independent laboratories and OGT.
Read and download the App notePresented at ESHG Virtual 2020, this poster outlines the results from over 200 intellectual disability and developmental research samples to demonstrate the efficiency of the CNV, SNV and LOH detection.
Read and download the Scientific posterPresented at ACMG 2020, this poster demonstrates the capability of a novel NGS assay designed to analyse genetic aberrations, including CNVs, SNVs, Indels and LOH, in intellectual disability and developmental delay research samples.
Read and download the Scientific posterThe primary objective of this study was to assess ctDNA clearance during neoadjuvant treatment as a correlate to effective response to treatment, as benchmarked by clinical complete response (cCR) and pathological complete response (pCR).
Read and download the Scientific posterMaking the change from microarrays to NGS is a daunting prospect, particularly when it comes to data analysis. This app note outlines some of the key features we’ve incorporated to help make the change from arrays to NGS as painless as possible.
Read and download the App note{{literatureDetailsPage.Summary}}
Read and download the {{literatureDetailsPage.FriendlyResorceType}}
Visit USA site
Visit Canada site
